Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Abbott’s Humira found to maintain remission in Crohn’s disease
Results from the phase III trial, dubbed CHARM, showed that remission rates were maintained through 56 weeks in patients who demonstrated response to Humira during the initial four-week
Results from the phase III trial, dubbed CHARM, showed that remission rates were maintained through 56 weeks in patients who demonstrated response to Humira during the initial four-week
The study is being conducted under the guidance of a special protocol assessment (SPA) provided by the FDA. The SPA indicates that if the trial successfully meets its
The phase I clinical trial of DCVax-Brain involved patients with Glioblastoma multiforme (GBM), the deadliest form of brain cancer. Dendritic cell-based immunotherapy, such as that used in the
The companies believe sc28AT, a CD28 antagonist in preclinical development, may block graft rejection as well as the initiation and development of autoimmune diseases, while keeping the body's
Ramelteon has a unique mechanism of action that selectively targets two receptors located in the brain's suprachiasmatic nucleus (SCN). The SCN is known as the body's 'master clock'
The first agreement relates to the use of Crucell's PER.C6 technology in the production of adenoviral vectors expressing ceNOS (constituted endothelial nitric oxide synthase) for the treatment of
The trial was designed to determine how immunomodulating agents such as CRx-102 would affect various systemic inflammatory markers in individuals with periodontitis. In the primary endpoint of reduction
The trials have two phases. The first phase will be a dose escalation to evaluate safety and immune responses. Initially, low doses of the two vaccine components will
“We are pleased to have licensed this technology platform from Kalium as it enables Urigen to develop important and innovative treatments for the urology medical community,” said William
TNX-650 targets interleukin 13 (IL-13), an important growth factor for malignant Hodgkin's lymphoma cells. In preclinical testing, TNX-650 inhibited the function of IL-13 and blocked the proliferation of